Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
Jaguar Health (NASDAQ:JAGX) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. The company's founder, president and CEO, Lisa Conte, will deliver a virtual presentation, which will be available on-demand starting at 7:00 AM Eastern on September 5, 2025.
The conference will be held in a hybrid format, offering both virtual access and in-person attendance at the Lotte New York Palace in New York City.
Jaguar Health (NASDAQ:JAGX) ha annunciato la sua partecipazione al prossimo H.C. Wainwright 27th Annual Global Investment Conference, in programma dall'8 al 10 settembre 2025. La fondatrice, presidente e CEO dell'azienda, Lisa Conte, terrà una presentazione virtuale che sarà disponibile on-demand a partire dalle 7:00 AM Eastern del 5 settembre 2025.
La conferenza si svolgerà in formato ibrido, con accesso virtuale e possibilità di partecipare di persona al Lotte New York Palace di New York City.
Jaguar Health (NASDAQ:JAGX) anunció su participación en la próxima H.C. Wainwright 27th Annual Global Investment Conference, programada del 8 al 10 de septiembre de 2025. La fundadora, presidenta y CEO de la compañía, Lisa Conte, ofrecerá una presentación virtual que estará disponible on‑demand a partir de las 7:00 AM Eastern del 5 de septiembre de 2025.
La conferencia se celebrará en formato híbrido, con acceso virtual y asistencia presencial en el Lotte New York Palace de la ciudad de Nueva York.
Jaguar Health (NASDAQ:JAGX)는 2025년 9월 8일부터 10일까지 예정된 H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다. 회사의 설립자이자 사장 겸 CEO인 리사 콘테(Lisa Conte)가 가상 프레젠테이션을 진행하며, 해당 발표는 2025년 9월 5일 동부시간(ET) 오전 7:00부터 온디맨드로 시청할 수 있습니다.
회의는 하이브리드 방식으로 진행되며, 가상 접속과 뉴욕시 롯데 뉴욕 팰리스(Lotte New York Palace)에서의 현장 참석이 모두 가능합니다.
Jaguar Health (NASDAQ:JAGX) a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference, prévue du 8 au 10 septembre 2025. La fondatrice, présidente et CEO de la société, Lisa Conte, fera une présentation virtuelle qui sera disponible en replay à partir de 7:00 AM Eastern le 5 septembre 2025.
La conférence se tiendra au format hybride, offrant un accès en ligne ainsi qu'une participation en personne au Lotte New York Palace à New York City.
Jaguar Health (NASDAQ:JAGX) gab seine Teilnahme an der bevorstehenden H.C. Wainwright 27th Annual Global Investment Conference bekannt, die vom 8. bis 10. September 2025 stattfindet. Die Gründerin, Präsidentin und CEO des Unternehmens, Lisa Conte, wird eine virtuelle Präsentation halten, die ab 7:00 AM Eastern am 5. September 2025 on‑demand verfügbar sein wird.
Die Konferenz wird hybrid abgehalten, mit virtuellem Zugang sowie persönlicher Teilnahme im Lotte New York Palace in New York City.
- None.
- None.
Click here to register
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which takes place September 8-10, 2025.
Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
When: On-demand virtual presentation available starting at 7:00 AM Eastern on Friday, September 5, 2025
Webcast Link: Click here to access the presentation
Where: The conference is taking place virtually and in-person at Lotte New York Palace, 455 Madison Avenue at 50th Street, New York City
To register to attend the conference, click here
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the September 2025 H.C. Wainwright 27th Annual Global Investment Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Jaguar Health (JAGX) presenting at the H.C. Wainwright Conference 2025?
Who is presenting for Jaguar Health at the H.C. Wainwright Conference?
Where is the H.C. Wainwright Conference 2025 being held?
How can investors access Jaguar Health's presentation at the H.C. Wainwright Conference?
